Aprea Therapeutics, Inc.
APRE Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$0.52
KIRA · Stoqly’s AI analyst, in plain words
- Aprea Therapeutics, Inc. had $0.3M of revenue in fiscal 2025, down 81.0% on the year before.
- Its operating margin was −4,630.4%, down 3,677.4 pts: of every 100 in sales, about −4,630 is left after running the business.
- Aprea Therapeutics, Inc. lost $12.6M in fiscal 2025.
Market cap
$27.7M
P/E
—
Revenue
$0.3M
Net income
−$12.6M
Free cash flow
—
Operating margin
−4,630.4%
Aprea Therapeutics, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−81.0%
No. Sales fell 81.0% last year.
Does it make a profit?
−4,408.5%
No. It lost money last year.
How healthy are the accounts?
0 / 7
Weak. It passes 0 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Aprea Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 16, 2026
- Legal name
- Aprea Therapeutics, Inc.
- CIK
- 0001781983
Aprea Therapeutics, Inc. · APRE
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | — | — | $0.6M | $1.5M | $0.3M |
| Revenue growth | — | — | — | 157.6% | −81.0% |
| Operating margin | — | — | −2,652.9% | −953.0% | −4,630.4% |
| Net income | −$37.1M | −$113M | −$14.3M | −$13.0M | −$12.6M |
| Net margin | — | — | −2,449.7% | −862.4% | −4,408.5% |
| Diluted EPS | −$34.88 | −$67.99 | −$3.95 | −$2.35 | −$1.93 |
| Cash | |||||
| Cash from operations | −$37.7M | −$25.0M | −$12.2M | −$13.6M | −$12.9M |
| Capital expenditure | — | — | $0.1M | $0.0M | — |
| Free cash flow | — | — | −$12.3M | −$13.6M | — |
| FCF margin | — | — | −2,104.0% | −903.2% | — |
| Share count change | 0.7% | 55.7% | 118.3% | 52.3% | 18.7% |
| Debt and strength | |||||
| Cash and short-term investments | $53.1M | $28.8M | $21.6M | $22.8M | $14.6M |
| Shareholders' equity | $49.5M | $25.6M | $17.0M | $19.3M | $12.4M |
| Current ratio | 7.7x | 9.4x | 5.1x | 7.0x | 5.6x |
| Returns and quality | |||||
| Return on equity | −58.5% | −299.8% | −67.1% | −71.5% | −79.4% |
| Return on tangible equity | −75.0% | −439.3% | −84.3% | −67.1% | −101.3% |
| Piotroski F-score | — | — | — | 3 | 0 |
| Altman Z'' | −2.0 | −42.8 | −40.6 | −37.8 | −64.8 |
Insiders bought, 12 months
$0.1M
3 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Aprea Therapeutics, Inc. · APRE
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.52 a share, the company is worth $27.7M.
Source: SEC EDGAR XBRL filings (CIK 0001781983). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.